Premium
Non‐migrainous headache for the evaluation of oral analgesics.
Author(s) -
Graffenried B,
Nuesch E
Publication year - 1980
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1980.tb01804.x
Subject(s) - dihydroergotamine , medicine , analgesic , aspirin , placebo , caffeine , anesthesia , pharmacology , migraine , alternative medicine , pathology
1 Eight double‐blind, randomized, placebo‐controlled, single‐dose, cross‐over studies were carried out to evaluate the usefulness of testing the acute analgesic effect of drugs in out‐patients with non‐ migrainous headache. 2 The reference compounds were either (1) aspirin, (2) a combination of aminopyrine, caffeine and butalbarbital (Optalidon), and (3) a combination of (2) with dihydroergotamine (Tonopan). 3 The test compounds were (1) proquazone, (2) fluproquazone and (3) and (4), new formulations of Optalidon and Tonopan in which the aminopyrine was replaced by propyphenazone. They were all found to be active. 4 A significant, dose‐response relationship was established for aspirin (250, 500 and 1000 mg). 5 It is concluded that the non‐ migrainous headache model is a practical, reproducible and sensitive method for the investigation of the acute efficacy of analgesics.